(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of 89.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.33%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.07%.
Sangamo Therapeutics's revenue in 2026 is $32,875,000.On average, 7 Wall Street analysts forecast SGMO's revenue for 2026 to be $16,563,941,221, with the lowest SGMO revenue forecast at $2,835,975,553, and the highest SGMO revenue forecast at $40,278,390,333. On average, 6 Wall Street analysts forecast SGMO's revenue for 2027 to be $56,746,430,625, with the lowest SGMO revenue forecast at $23,347,333,625, and the highest SGMO revenue forecast at $92,428,306,239.
In 2028, SGMO is forecast to generate $71,114,745,305 in revenue, with the lowest revenue forecast at $6,595,291,984 and the highest revenue forecast at $150,160,665,716.